Our study found respectively 72.2%, 90%, 43.5%, 77.8%, and 73.7% of UC, squamous carcinoma, glandular carcinoma, nested variant, and micropapillary variant expressing both TROP-2 and NECTIN-4, while 10.5% of small cell carcinoma, which may have some implications for combination and sequence therapies. This evidence concerns the gene NECTIN1 and small cell carcinoma.